Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03335072 · ClinicalTrials.gov registry record · Phase 4

Kebele Elimination of Trachoma for Ocular Health

A Phase 4 study of Trachoma, sponsored by University of California, San Francisco.

Active
Registry status
Phase 4
Development phase
320,000
Enrollment target
2
Study locations

NCT03335072: Active Phase 4 study of Trachoma, sponsored by University of California, San Francisco.

NCT03335072 is a Phase 4 study of Trachoma that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 320,000 participants, above the 565-participant average among 4 other Trachoma trials with a reported enrollment target (56537% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03335072, a Phase 4 study of Trachoma, is active but no longer recruiting, sponsored by University of California, San Francisco.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
320,000 participants
Enrollment target
2
Study locations

Study Summary

The investigators propose a cluster-randomized clinical trial to determine whether an intensive, targeted azithromycin distribution strategy is effective for elimination of trachoma at the kebele level compared to the World Health Organization (WHO) recommendation of annual azithromycin distribution.

Primary Outcome

Assessed by PCR

Conditions Studied

Interventions

  • DRUG Azithromycin

Study Locations (2)

California

  • UCSF Proctor Foundation - San Francisco

Other

  • Eyu-Ethiopia - Bahir Dar

Trial Details

FieldValue
Enrollment Target 320,000 participants
Start Date 2022-02-07
Est. Completion 2028-03-01
Phase Phase 4

What the registry record for NCT03335072 still lists

NCT03335072 is an interventional study that assigns participants to a tested intervention. Its 320,000 participants enrollment target places it among the larger protocols in the corpus, above the 565-participant average among 4 other Trachoma trials with a reported enrollment target (56537% higher).

The record links to 1 condition, with Trachoma appearing as the primary indexed condition, and to 1 intervention - of which Azithromycin is the first listed.

NCT03335072 reports a single indexed study location in California, Other.

Frequently Asked Questions

What is clinical trial NCT03335072 about?

NCT03335072 is a clinical study titled "Kebele Elimination of Trachoma for Ocular Health". The investigators propose a cluster-randomized clinical trial to determine whether an intensive, targeted azithromycin distribution strategy is effective for elimination of trachoma at the kebele level compared to the World Health Organization (WHO) recommendation of annual azithromycin distribution...

What is the current status of trial NCT03335072?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 320,000 participants. The study started on 2022-02-07. Estimated completion is 2028-03-01.

What conditions does trial NCT03335072 study?

This clinical trial studies the following conditions: Trachoma.

What interventions are being tested in trial NCT03335072?

The interventions under investigation include: Azithromycin (DRUG).

Who is sponsoring clinical trial NCT03335072?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03335072 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Trachoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05668637 · 318,542 participants

    Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support

  • NCT05365048 · 301,201 participants · NA

    Provider Recommendation and HPV Vaccination

  • NCT02280733 · 300,000 participants

    A Real-World Registry of Chronic Wounds and Ulcers

  • NCT06694181 · 300,000 participants

    Safe and Explainable AI

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03335072, the US trial registry maintained by the National Library of Medicine. NCT03335072 (large enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.